Published in Eur J Immunol on August 01, 2006
IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med (2010) 2.21
Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells. J Immunol (2008) 1.58
Dexamethasone promotes tolerance in vivo by enriching CD11clo CD40lo tolerogenic macrophages. Eur J Immunol (2012) 1.45
Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS One (2009) 1.44
Sleep-dependent activity of T cells and regulatory T cells. Clin Exp Immunol (2008) 1.16
Bcl-2-regulated cell death signalling in the prevention of autoimmunity. Cell Death Dis (2010) 1.04
Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitis. BMC Immunol (2007) 1.04
Th17 cells and Tregs: unlikely allies. J Leukoc Biol (2014) 1.03
Cutting edge: Immunosuppressant as adjuvant for tolerogenic immunization. J Immunol (2008) 1.00
Repeated bouts of aerobic exercise enhance regulatory T cell responses in a murine asthma model. Brain Behav Immun (2009) 0.99
T regulatory cells: aid or hindrance in the clearance of disease? J Cell Mol Med (2008) 0.93
In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration. PLoS One (2012) 0.92
Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis. Clin Exp Immunol (2009) 0.89
T regulatory cells: an overview and intervention techniques to modulate allergy outcome. Clin Mol Allergy (2009) 0.89
Glucocorticoids alleviate intestinal ER stress by enhancing protein folding and degradation of misfolded proteins. J Exp Med (2013) 0.88
Development of novel treatment strategies for inflammatory diseases-similarities and divergence between glucocorticoids and GILZ. Front Pharmacol (2014) 0.88
Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis. Acta Neurol Scand (2009) 0.88
Histone deacetylase inhibitors and transplantation. Curr Opin Immunol (2007) 0.87
Regulatory T Cells: Serious Contenders in the Promise for Immunological Tolerance in Transplantation. Front Immunol (2015) 0.87
Diminution of Circulating CD4+CD25 high T cells in naïve Crohn's disease. Dig Dis Sci (2008) 0.86
In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo. Cytokine (2013) 0.84
Influence of short-term glucocorticoid therapy on regulatory T cells in vivo. PLoS One (2011) 0.84
The majority of HIV type 1 DNA in circulating CD4+ T lymphocytes is present in non-gut-homing resting memory CD4+ T cells. AIDS Res Hum Retroviruses (2013) 0.83
Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity. Int J Mol Sci (2014) 0.81
CD8⁺ Treg cells associated with decreasing disease activity after intravenous methylprednisolone pulse therapy in lupus nephritis with heavy proteinuria. PLoS One (2014) 0.80
Chemokine-mediated redirection of T cells constitutes a critical mechanism of glucocorticoid therapy in autoimmune CNS responses. Acta Neuropathol (2014) 0.80
Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica (2015) 0.80
Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus. PLoS One (2015) 0.79
Impact of Immune-Modulatory Drugs on Regulatory T Cell. Transplantation (2016) 0.77
Experimental advances in understanding allergic airway inflammation. Front Biosci (Schol Ed) (2013) 0.77
Increased presence of FOXP3+ regulatory T cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral blood. PLoS One (2014) 0.76
Evidence for Direct Inhibition of MHC-Restricted Antigen Processing by Dexamethasone. Immune Netw (2014) 0.76
IKKβ-mediated inflammatory myeloid cell activation exacerbates experimental autoimmune encephalomyelitis by potentiating Th1/Th17 cell activation and compromising blood brain barrier. Mol Neurodegener (2016) 0.76
Oriental Medicine Samhwangsasim-tang Alleviates Experimental Autoimmune Encephalomyelitis by Suppressing Th1 Cell Responses and Upregulating Treg Cell Responses. Front Pharmacol (2017) 0.75
Short-term intratracheal use of PEG-modified IL-2 and glucocorticoid persistently alleviates asthma in a mouse model. Sci Rep (2016) 0.75
Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells. Cell Mol Immunol (2012) 0.75
Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity. Clin Vaccine Immunol (2007) 0.75
Cognitive disorders in mice: cytokine signaling pathways as therapeutic targets. OMICS (2012) 0.75
Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Front Pharmacol (2017) 0.75
Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science (2002) 4.45
Mammalian defensins in immunity: more than just microbicidal. Trends Immunol (2002) 3.52
Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol (2007) 2.92
Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol (2004) 2.72
Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol (2003) 2.62
High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol (2006) 2.44
Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med (2008) 2.41
Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3. Proc Natl Acad Sci U S A (2003) 2.32
Alarmins: awaiting a clinical response. J Clin Invest (2012) 2.19
Cellular pharmacology studies of shikonin derivatives. Phytother Res (2002) 2.09
Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol (2007) 2.08
Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med (2008) 2.04
Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin. Blood (2010) 1.85
A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci U S A (2005) 1.82
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med (2002) 1.78
Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation (2003) 1.71
Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol (2008) 1.71
Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J Immunol (2005) 1.62
Alarmins link neutrophils and dendritic cells. Trends Immunol (2009) 1.61
Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. J Immunol (2010) 1.59
Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc Natl Acad Sci U S A (2002) 1.55
The structure of human macrophage inflammatory protein-3alpha /CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins. J Biol Chem (2002) 1.53
Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. Cancer Res (2005) 1.51
Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. J Immunol (2007) 1.45
Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur J Immunol (2010) 1.37
Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol (2004) 1.37
Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death. Eur J Immunol (2004) 1.36
Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J Immunol (2004) 1.33
Identification and Biological Characterization of Mouse beta-defensin 14, the orthologue of human beta-defensin 3. J Biol Chem (2007) 1.32
BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice. J Leukoc Biol (2005) 1.31
Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization. J Leukoc Biol (2003) 1.30
Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J Immunol (2008) 1.30
Natural cytotoxicity uncoupled from the Syk and ZAP-70 intracellular kinases. Nat Immunol (2002) 1.29
Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood (2003) 1.29
Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob Agents Chemother (2003) 1.29
mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res (2011) 1.28
Proinflammatory chemokines, such as C-C chemokine ligand 3, desensitize mu-opioid receptors on dorsal root ganglia neurons. J Immunol (2004) 1.27
TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J Immunol (2012) 1.26
Painful pathways induced by TLR stimulation of dorsal root ganglion neurons. J Immunol (2011) 1.24
Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. J Immunol (2010) 1.23
Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst (2005) 1.21
Aberrant DAP12 signaling in the 129 strain of mice: implications for the analysis of gene-targeted mice. J Immunol (2002) 1.20
Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor. J Immunol (2004) 1.20
Adenosine A2a receptors induce heterologous desensitization of chemokine receptors. Blood (2006) 1.19
Monocyte chemoattractant protein-1/CCL2 produced by stromal cells promotes lung metastasis of 4T1 murine breast cancer cells. PLoS One (2013) 1.18
Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. J Immunol (2008) 1.18
Pertussis toxin as an adjuvant suppresses the number and function of CD4+CD25+ T regulatory cells. Eur J Immunol (2006) 1.16
TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Curr Dir Autoimmun (2010) 1.14
Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res (2006) 1.13
High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses. J Exp Med (2011) 1.12
Defensin participation in innate and adaptive immunity. Curr Pharm Des (2007) 1.12
Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett (2011) 1.11
Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood (2003) 1.11
In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J Immunol (2008) 1.10
Transactivation of the epidermal growth factor receptor by formylpeptide receptor exacerbates the malignant behavior of human glioblastoma cells. Cancer Res (2007) 1.10
Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol (2005) 1.09
Cutting edge: bone morphogenetic protein antagonists Drm/Gremlin and Dan interact with Slits and act as negative regulators of monocyte chemotaxis. J Immunol (2004) 1.07
Ca2+-independent protein kinase Cs mediate heterologous desensitization of leukocyte chemokine receptors by opioid receptors. J Biol Chem (2003) 1.07
Ribonuclease is partly responsible for the HIV-1 inhibitory effect activated by HLA alloantigen recognition. AIDS (2003) 1.06
Chemokine-like receptor 1 (CMKLR1) and chemokine (C-C motif) receptor-like 2 (CCRL2); two multifunctional receptors with unusual properties. Exp Cell Res (2010) 1.06
Chemerin reveals its chimeric nature. J Exp Med (2008) 1.06
Ligand-induced partitioning of human CXCR1 chemokine receptors with lipid raft microenvironments facilitates G-protein-dependent signaling. Mol Cell Biol (2005) 1.05
STAT1 activation regulates proliferation and differentiation of renal progenitors. Cell Signal (2010) 1.05
Gene from a psoriasis susceptibility locus primes the skin for inflammation. Sci Transl Med (2010) 1.04
Up-regulated expression and activation of the orphan chemokine receptor, CCRL2, in rheumatoid arthritis. Arthritis Rheum (2004) 1.03
Effects of Shuanghuanglian and Qingkailing, two multi-components of traditional Chinese medicinal preparations, on human leukocyte function. Life Sci (2002) 1.02
Increased bone marrow allograft rejection by depletion of NK cells expressing inhibitory Ly49 NK receptors for donor class I antigens. Blood (2002) 1.00
Tannic acid is an inhibitor of CXCL12 (SDF-1alpha)/CXCR4 with antiangiogenic activity. Clin Cancer Res (2003) 1.00
[Gd@C(82)(OH)(22)](n) nanoparticles induce dendritic cell maturation and activate Th1 immune responses. ACS Nano (2010) 1.00
Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells. Int Immunopharmacol (2011) 0.99
Human dendritic cells express functional formyl peptide receptor-like-2 (FPRL2) throughout maturation. J Leukoc Biol (2002) 0.97
TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol (2011) 0.97
Specific binding and chemotactic activity of mBD4 and its functional orthologue hBD2 to CCR6-expressing cells. J Biol Chem (2010) 0.96
Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems. J Leukoc Biol (2005) 0.96
Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components. Cell Mol Immunol (2004) 0.96
Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat Med (2003) 0.96
Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. J Immunol (2003) 0.95
Negative regulation of CXCR4-mediated chemotaxis by the lipid phosphatase activity of tumor suppressor PTEN. Blood (2005) 0.95
NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function. J Immunol (2006) 0.95